Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

被引：53

作者：

Fehniger, Todd A. ^{[1
]}

Byrd, John C. ^{[2
,3
]}

Marcucci, Guido ^{[2
,4
]}

Abboud, Camille N. ^{[1
]}

Kefauver, Cheryl ^{[2
]}

Payton, Jacqueline E. ^{[5
]}

Vij, Ravi ^{[1
]}

Blum, William ^{[2
]}

机构：

[1] Washington Univ, Div Oncol, Dept Internal Med, Siteman Canc Ctr, St Louis, MO USA

[2] Ohio State Univ, Div Hematol & Oncol, Ctr Comprehens Canc, Dept Med, Columbus, OH 43210 USA

[3] Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA

[4] Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA

[5] Washington Univ, Dept Pathol & Immunol, Siteman Canc Ctr, St Louis, MO USA

来源：

BLOOD | 2009年 / 113卷 / 05期

基金：

美国国家卫生研究院;

关键词：

INCREASED FLT3 EXPRESSION; MYELODYSPLASTIC SYNDROMES; MULTIPLE-MYELOMA; OLDER PATIENTS; THERAPY; ADULT; CYTOGENETICS; DELETION; PHASE-2; CANCER;

D O I：

10.1182/blood-2008-04-152678

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897. (Blood. 2009;113:1002-1005)

引用

页码：1002 / 1005

页数：4

共 20 条

[1] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[2] Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia [J].

Dicker, Frank ;

Haferlach, Claudia ;

Kern, Wolfgang ;

Haferlach, Torsten ;

Schnittger, Susanne .

BLOOD, 2007, 110 (04) :1308-1316

[3] Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein [J].

DiMartino, JF ;

Lacayo, NJ ;

Varadi, M ;

Li, L ;

Saraiya, C ;

Ravindranath, Y ;

Yu, R ;

Sikic, B ;

Raimondi, SC ;

Dahl, G .

LEUKEMIA, 2006, 20 (03) :426-432

[4]

DOHNER H, 1990, BLOOD, V76, P1614

[5] Identification of RPS14 as a 5q- syndrome gene by RNA interference screen [J].

Ebert, Benjamin L. ;

Pretz, Jennifer ;

Bosco, Jocelyn ;

Chang, Cindy Y. ;

Tamayo, Pablo ;

Galili, Naomi ;

Raza, Azra ;

Root, David E. ;

Attar, Eyal ;

Ellis, Steven R. ;

Golub, Todd R. .

NATURE, 2008, 451 (7176) :335-U7

[6] General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia [J].

Estey, EH .

SEMINARS IN HEMATOLOGY, 2006, 43 (02) :89-95

[7] Acute myeloid leukemia and myelodysplastic syndromes in older patients [J].

Estey, Elihu .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (14) :1908-1915

[8] Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:: results from Cancer and Leukemia Group B 8461 [J].

Farag, Sherif S. ;

Archer, Kellie J. ;

Mrozek, Krzysztof ;

Ruppert, Amy S. ;

Carroll, Andrew J. ;

Vardiman, James W. ;

Pettenati, Mark J. ;

Baer, Maria R. ;

Qumsiyeh, Mazin B. ;

Koduru, Prasad R. ;

Ning, Yi ;

Mayer, Robert J. ;

Stone, Richard M. ;

Larson, Richard A. ;

Bloomfield, Clara D. .

BLOOD, 2006, 108 (01) :63-73

[9] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[10] Efficacy of lenalidomide in myelodysplastic syndromes [J].

List, A ;

Kurtin, S ;

Roe, DJ ;

Buresh, A ;

Mahadevan, D ;

Fuchs, D ;

Rimsza, L ;

Heaton, R ;

Knight, R ;

Zeldis, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :549-557

← 1 2 →